Target intelligence / Profile preview

Protein N-terminal asparagine amidase (NTAN1)

Target
NTAN1
Molecular classification
Enzyme, Cysteine hydrolase, Member of CNF1/YfiH-like cysteine hydrolase family
01

Overview

Protein N-terminal asparagine amidase (NTAN1) is an enzyme that catalyzes the conversion (deamidation) of N-terminal asparagine residues to aspartate on substrate proteins, a key step in the eukaryotic N-end rule pathway of targeted protein degradation. NTAN1 exhibits high specificity for N-terminal Asn, preferring substrates with hydrophobic second-position residues, and functions via a CNF1/YfiH-like cysteine hydrolase fold with a conserved catalytic triad. Once deamidated, the N-terminal aspartate undergoes arginylation and subsequent ubiquitin-dependent proteasomal degradation. NTAN1 activity is implicated in maintenance of cellular protein turnover and normal neurological function, with genetic variants associated with certain diseases. There are currently no known drugs targeting NTAN1 directly[1][2][3][5].

Other names
Protein N-terminal Asn amidasePNAAPNADprotein NH2-terminal asparagine amidohydrolaseprotein NH2-terminal asparagine deamidaseprotein NTN-amidase
02

Mechanism of action

(For hypothetical drugs): Inhibition or modulation of NTAN1 would block the deamidation of N-terminal Asn, potentially altering protein stability and turnover via the N-end rule pathway

03

Biological functions

Protein degradation via the N-end rule pathwayDeamidation of N-terminal asparagine residues to aspartateRegulation of intracellular protein half-life
04

Disease associations

Type 1 diabetes mellitus (genetic association)Rheumatoid arthritis interstitial lung disease (genetic association)Neurological defects (in mouse models upon deficiency)
05

Safety considerations

Potential disruption of protein homeostasisRisk of neurological and metabolic defects based on knockout phenotypes in animal models

Beyond the preview

Go deeper on Protein N-terminal asparagine amidase (NTAN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein N-terminal asparagine amidase (NTAN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call